학술논문
Immune checkpoint inhibitor‐related adverse events in lung cancer: Real‐world incidence and management practices of 1905 patients in China
Document Type
article
Author
Yuequan Shi; Jian Fang; Chengzhi Zhou; Anwen Liu; Yan Wang; Qingwei Meng; Cuimin Ding; Bin Ai; Yangchun Gu; Yu Yao; Hong Sun; Hui Guo; Cuiying Zhang; Xia Song; Junling Li; Bei Xu; Zhiqiang Han; Meijun Song; Tingyu Tang; Peifeng Chen; Hongmin Lu; Yongjie Shui; Guangyuan Lou; Dongming Zhang; Jia Liu; Xiaoyan Liu; Xiangning Liu; Xiaoxing Gao; Qing Zhou; Minjiang Chen; Jing Zhao; Wei Zhong; Yan Xu; Mengzhao Wang
Source
Thoracic Cancer, Vol 13, Iss 3, Pp 412-422 (2022)
Subject
Language
English
ISSN
1759-7714
1759-7706
1759-7706
Abstract
Abstract Background Immune checkpoint inhibitors (ICIs) are the standard treatment for advanced lung cancer, but immune‐related adverse events (irAEs) remain poorly understood, especially in a real‐world setting. Methods A multicenter observational study was conducted. Medical records of lung cancer patients treated with ICIs at 26 hospitals from January 1, 2015, to February 28, 2021, were retrieved. Types of ICIs included antiprogrammed cell death 1 or antiprogrammed cell death ligand 1 (PD‐L1) monotherapy, anticytotoxic T‐lymphocyte antigen‐4 monotherapy, or combination therapy. Results In total, 1905 patients with advanced lung cancer were evaluated. The median age was 63 (range 28–87) years, and the male/female ratio was 3.1:1 (1442/463). The primary histological subtype was adenocarcinoma (915). A total of 26.9% (512/1905) of the patients developed 671 irAEs, and 5.8% (110/1905) developed 120 grade 3–5 irAEs. Median duration from ICI initiation to irAEs onset was 56 (range 0–1160) days. The most common irAEs were thyroid dysfunction (7.2%, 138/1905), pneumonitis (6.5%, 124/1905), and dermatological toxicities (6.0%, 115/1905). A total of 162 irAEs were treated with steroids and 11 irAEs led to death. Patients with positive PD‐L1 expression (≥1%) and who received first‐line ICI treatment developed more irAEs. Patients who developed irAEs had a better disease control rate (DCR, 71.3% [365/512] vs. 56.0% [780/1145]; p